Market Overview

Adamis Has 'Favorable' Pipeline Setup, Says Bullish Raymond James

Adamis Has 'Favorable' Pipeline Setup, Says Bullish Raymond James
Related ADMP
48 Biggest Movers From Yesterday
34 Stocks Moving In Thursday's Mid-Day Session
Insys Therapeutics Is Ready To Change Lanes And Shift Gears In 2019 (Seeking Alpha)

Adamis Pharmaceuticals Corp (NASDAQ: ADMP) announced its NDA filing Friday for a fast-dissolving sublingual tadalafil tablet for erectile dysfunction.

The Analyst

Raymond James analyst Elliot Wilbur maintained an Outperform on Adamis.

The Thesis

The submission of the NDA is positive, as an approval would place Adamis in the $4-billion-plus phosphodiesterase inhibitor market, Wilbur said in a Monday note.

Even a small conversion rate could translate to a $150-million top-line opportunity, the analyst said. 

Raymond James expects the FDA decision to come through in the fourth quarter, with a potential commercial launch in 2020.

The stock price has factored in a Symjepi launch in Q1, but is not adequately reflecting other pipeline assets, Wilbur said. 

The approval of tadalafil would pitch Adamis against Eli Lilly And Co (NYSE: LLY)'s Cialis and Pfizer Inc. (NYSE: PFE)'s recently genericized Viagra, as well as vardenafil, a combo drug consisting of Levitra and Staxyn from GlaxoSmithKline plc (NYSE: GSK).

"We reiterate our Outperform rating as the company continues to make forward progress and provides better visibility on timelines," Wilbur said. "We believe the risk-reward scenario given the pipeline setup is favorable with significant upside." 

The Price Action

Adamis shares were up 3.11 percent at $2.32 at the time of publication Wednesday. 

Related Links:

Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates

6 Valuable Pipeline Drugs With Upcoming Catalysts

Latest Ratings for ADMP

Nov 2018B. Riley FBRDowngradesBuyNeutral
May 2018Maxim GroupMaintainsBuyBuy
Apr 2018H.C. WainwrightInitiates Coverage OnBuy

View More Analyst Ratings for ADMP
View the Latest Analyst Ratings

Posted-In: Elliot Wilbur Raymond JamesAnalyst Color Biotech Reiteration Analyst Ratings General Best of Benzinga


Related Articles (GSK + ADMP)

View Comments and Join the Discussion!

Latest Ratings

SSTIImperial CapitalDowngrades49.0
OSPNImperial CapitalDowngrades20.0
ENBLStifel NicolausUpgrades17.0
FAROGabelli & Co.Upgrades0.0
BDCLongbow ResearchDowngrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Rapid-Fire Pitch: Project44 And The Art Of The Possible

Mid-Morning Market Update: Markets Open Lower; Omega Healthcare Investors to Buy MedEquities Realty Trust